MRSA Drugs Global Strategic Research Report 2024: Market to Reach $1.6 Billion by 2030 - Glycopeptides & Lipoglycopeptides to Account for $660 Million
May 13, 2024 09:55 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "MRSA Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global MRSA Drugs Market to Reach $1.6...
Lifestyle Drugs Global Strategic Business Report 2024
May 13, 2024 09:11 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Lifestyle Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Lifestyle Drugs Market to Reach...
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
May 09, 2024 14:51 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first...
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 08:00 ET
|
Phathom Pharmaceuticals
Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of $1.9 million reported for the first full...
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
May 08, 2024 16:05 ET
|
Assembly Biosciences, Inc.
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on...
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
May 06, 2024 06:05 ET
|
MannKind
MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF SERIOUS LUNG DISEASE
Interstitial Cystitis Drugs Global Market Report 2024, By Drugs (Pentosan Polysulfate Sodium; Dimethyl Sulfoxide), By Type (Oral Therapy; Intravesical Therapy) and By Distribution Channel
May 06, 2024 04:06 ET
|
Research and Markets
Dublin, May 06, 2024 (GLOBE NEWSWIRE) -- The "Interstitial Cystitis Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The interstitial cystitis drugs...
Global Migraine Drugs Market Report 2024, By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants), By Route of Administration (Oral, Injectable) and By End-User
May 06, 2024 04:05 ET
|
Research and Markets
Dublin, May 06, 2024 (GLOBE NEWSWIRE) -- The "Migraine Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The migraine drugs market size has grown strongly...
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
May 03, 2024 07:00 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1...
Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena Pharmaceuticals, Pfizer, Abivax, Janssen, Celgene, Eli Lilly and Company, Merck Sharp & Dohme LLC, T
May 02, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena...